Effectiveness of Anti‐ IL ‐13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48‐Week Outcomes by Lebrikizumab and Tralokinumab
The Journal of Dermatology · 2026-05 · 53 (5) · 780-788
DOI: 10.1111/1346-8138.70183 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, online erschienen am 11.02.2026. Verfasst von Mizuki Shiba und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-13, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Maruho Takagi Dermatology Foundation.
Abstract (Originalsprache)
Anti–interleukin‐13 antibodies, lebrikizumab, and tralokinumab are effective for atopic dermatitis (AD); however, real‐world data on 1‐year effectiveness for head and neck (H&N) lesions are limited. To evaluate the effectiveness of 48‐week lebrikizumab or tralokinumab treatment on H&N lesions in patients with moderate‐to‐severe AD. We conducted a two‐center retrospective study of Japanese AD patients treated with lebrikizumab ( n = 160) or tralokinumab ( n = 171). H&N eczema area and severity index (EASI) was assessed through 48 weeks in total patients or subgroups of baseline H&N EASI < 3 or ≥ 3. Lebrikizumab and tralokinumab rapidly reduced H&N EASI by Week 4, which was maintained through Week 48. At Week 48, achievement rates of H&N EASI 75, 90, or 100 were 77.3%, 37.3%, or 17.3% with lebrikizumab, and 75.0%, 44.8%, or 29.2% with tralokinumab, respectively. In lebrikizumab treatment, patients with baseline H&N EASI ≥ 3 showed numerically higher achievement rates of H&N EASI 90 at Week 16 and 48 compared to those with baseline H&N EASI < 3, whereas the results were the trend differed in tralokinumab treatment. This subgroup observation was limited to small baseline H&N EASI ≥ 3 subgroups and may not be generalizable. Taken together, treatment with lebrikizumab and tralokinumab rapidly reduced H&N EASI by Week 4, and these improvements were maintained through Week 48.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei-Ichiro Motegi, Naoko Kanda
Förderung
- Maruho Takagi Dermatology Foundation
Zitieren
APA
Shiba, M., Hagino, T., Uchiyama, A., Saeki, H., Fujimoto, E., Motegi, S. I., & Kanda, N. (2026). Effectiveness of Anti‐ IL ‐13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48‐Week Outcomes by Lebrikizumab and Tralokinumab. The Journal of Dermatology, 53(5), 780-788. https://doi.org/10.1111/1346-8138.70183
Vancouver
Shiba M, Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi SI, et al. Effectiveness of Anti‐ IL ‐13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48‐Week Outcomes by Lebrikizumab and Tralokinumab. The Journal of Dermatology. 2026;53(5):780-788. doi:10.1111/1346-8138.70183
BibTeX
@article{Shiba2026,
author = {Shiba, Mizuki and Hagino, Teppei and Uchiyama, Akihiko and Saeki, Hidehisa and Fujimoto, Eita and Motegi, Sei-Ichiro and Kanda, Naoko},
title = {Effectiveness of Anti‐ IL ‐13 Antibodies on Head and Neck Lesions in Atopic Dermatitis: 48‐Week Outcomes by Lebrikizumab and Tralokinumab},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {5},
pages = {780--788},
doi = {10.1111/1346-8138.70183}
}
EUVIMED